{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"<p>Reduktion postoperativer Hernien nach Laparotomien durch small stitch Bauchdeckenverschluss ohne vs. mit prophylaktischer Netzimplantation</p><p>DRKS00017517</p>","eudractNumber":null,"id":6661,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_10","name":"Phase IIIB"},"recruitmentStart":"2020-01-14T11:37:26+01:00","shortTitle":"HULC","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<p>Reduktion postoperativer Hernien nach Laparotomien durch small stitch Bauchdeckenverschluss ohne vs. mit prophylaktischer Netzimplantation</p><p><b>DRKS00017517</b></p><p><b><br /></b></p>","eudractNumber":null,"id":5658,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2020-04-27T12:31:18+02:00","shortTitle":"HULC","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A non-interventional study of melphalan flufenamide (melflufen, Pepaxti) in combination with dexamethasone in patients with relapsed and/ or refractory multiple myeloma (RRMM) according to the approved label<br /><div><br /></div><div>DRKS00033264</div>","eudractNumber":null,"id":10626,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-11-01T08:30:35+01:00","shortTitle":"Harbour","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Stereotactic body\nradiotherapy (SBRT) for primary liver tumors (HepReg) - an International Multicentre Registry Collecting Data on Patients treated with SBRT for HCC","eudractNumber":null,"id":10200,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2026-03-02T13:32:31+01:00","shortTitle":"HepReg","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Establishment of a national registry for the Evaluation and improvement of Risk-adjusted prevention for hereditary breast and ovarian cancer","eudractNumber":null,"id":6724,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2021-01-01T13:47:32+01:00","shortTitle":"HerediCaRe","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Wechselseitiger Patienten -Arzt-Austausch in der Versorgung bei Brustkrebs mit dem Ziel der gemeinsamen Erarbeitung neuer Patienten-orientierter Strukturen.","eudractNumber":null,"id":12056,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":null,"shortTitle":"High WAVES","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"International HIT-MED Registry: For children, adolescents, and adults \nwith medulloblastoma, ependymoma, pineoblastoma, CNS-primitive \nneuroectodermal tumours","eudractNumber":null,"id":1592,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT02417324","phase":null,"recruitmentStart":"2015-01-01T11:20:20+01:00","shortTitle":"I-HIT MED Registry","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>Neuer zielgerichteter Therapieansatz beim IDH1 R132- mutierten Cholangiokarzinom</div><div>Evaluation der Wirksamkeit, Sicherheit und Lebensqualit&#228;t der Behandlung mit Ivosidenib</div>","eudractNumber":null,"id":10706,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-11-11T09:14:05+01:00","shortTitle":"IDHIRA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Neuer zielgerichteter Therapieansatz beim IDH1 R132- mutierten Cholangiokarzinom</div><div>Evaluation der Wirksamkeit, Sicherheit und Lebensqualit&#228;t der Behandlung mit Ivosidenib</div>","eudractNumber":null,"id":11564,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-10-06T09:14:01+02:00","shortTitle":"IDHIRA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Phase 1 study evaluating genetically modified autologous T cells expressing a T cell recepter recognizing a cancer/germline Antigen in patients with recurrent and/or refractory solid Tumors (ACTengine IMA203-101)</div><div><br /></div><div>Target: PRAME</div>","eudractNumber":"2019-002370-31","id":5992,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"},{"name":"PRAME (Nuclear Receptor Transcriptional Regulator)","id":"mt_171"}],"nctNumber":"NCT03686124","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2020-08-13T10:58:11+02:00","shortTitle":"IMA203-101 (Immatics-PRAME)","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]}]}